Tag Archives: biopharmaceutical

ILC Dover to Open New Production Facility in Blarney, Ireland for Added Capabilities, Capacity and Jobs

Expansion positions ILC as leading single use powder handling solutions provider to the global pharma & biopharma market FREDERICA, DE, USA, 01-Nov-2018 — /EuropaWire/ — ILC Dover, a global leader in flexible containment solutions for the pharmaceutical and biopharmaceutical industry … Read the full press release

SGS to expand its biopharmaceutical testing capabilities in Geneva with a new 200m2 laboratory

GENEVA, 04-Sep-2018 — /EuropaWire/ — SGS, a leading bio/pharmaceutical analytical and bioanalytical contract solutions provider, today announced it is expanding its biopharmaceutical testing capabilities in Geneva, Switzerland with a new 200m2 laboratory. The laboratory will be equipped with a number of … Read the full press release

John C. Reed, M.D. Ph.D. to succeed Elias Zerhouni, M.D. as Head of Global Research and Development at Sanofi

PARIS, 25-Apr-2018 — /EuropaWire/ — Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June 30th, 2018, after more than 9 years of distinguished service with the company. He will be succeeded in the post … Read the full press release

Sanofi acquires Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders

Expands Sanofi’s presence in specialty care and strengthens leadership in rare diseases  Adds leader in the growing hemophilia market and provides platform for expansion in other rare blood disorders  Drives meaningful shareholder value with ROIC expected to exceed cost of … Read the full press release

200 healthcare decision-makers gather to address the looming challenges of cost, access and sustainability in the coming wave of high-value medicines

LONDON, 01-Dec-2017 — /EuropaWire/ — On December 5-6, 2017, 200 high-level experts from government, academia, biopharmaceutical developers and patient organisations convene in London (UK) to address the mounting challenge of accessibility and patient access to high-value, high-cost medical therapies. The … Read the full press release

SAVOR-TIMI-53 cardiovascular outcomes trial of ONGLYZA® results announced by AstraZeneca and Bristol-Myers Squibb

20-6-2013 — /europawire.eu/ — AstraZeneca and Bristol-Myers Squibb announced today top-line results of the Phase IV SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin). In this study of adult patients with … Read the full press release